Deutsche Bank Aktiengesellschaft Reiterates Hold Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by research analysts at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Tuesday, Digital Look reports. They currently have a £117 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential downside of 3.35% from the company’s previous close.

AZN has been the subject of several other reports. Citigroup lifted their target price on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a report on Tuesday, September 8th. Berenberg Bank lowered their target price on AstraZeneca from £160 to £150 and set a “buy” rating for the company in a research note on Tuesday. Finally, Jefferies Financial Group restated a “buy” rating and set a £175 target price on shares of AstraZeneca in a report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of £150.

AstraZeneca Stock Performance

LON AZN opened at £121.06 on Tuesday. AstraZeneca has a 1 year low of £107.84 and a 1 year high of £157.32. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. The firm’s 50 day simple moving average is £122.84 and its 200 day simple moving average is £135.11. The firm has a market capitalization of £187.75 billion, a price-to-earnings ratio of 18.12, a P/E/G ratio of 0.86 and a beta of 0.20.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.